Completion of SON-1010 (IL12-FHAB) monotherapy dose escalation in Phase 1 SB101 trial; Stable disease (SD) at four months post-initiation of ...
During a Case-Based Roundtable® event, Neeraj Agarwal, MD, and participants discussed how they might determine which ...
AnaptysBio (NASDAQ:ANAB – Get Free Report)‘s stock had its “outperform” rating restated by equities research analysts at Wedbush in a report issued on Wednesday,RTT News reports. They presently have a ...
Disease control rate (DCR) of 78% (7 of 9) in combination escalation arm of MDNA11 with Merck’s (known as MSD outside of Canada and the US) ...
As always, the chat will be recreated in real time beneath the window so that you can read it like any other article at ...
It is the second drug in the PD-1/PD-L1 inhibitor class to be cleared in a subcutaneous injection form by the FDA after Roche's Tecentriq Hybreza (atezolizumab and hyaluronidase) – which got a ...
There has been a lot of talk about drugs targeting both PD-1 and VEGF stealing the crown held by MSD's Keytruda in cancer immunotherapy. Now, the company has made a move to try to make sure it isn ...
Background Early-life inflammation has long been recognised as a key pathophysiological process in the evolution of cystic ...
Background Healthcare patient safety investigations inappropriately focus on individual culpability and the target of ...
In summary, enalapril significantly mitigated multiple pathological markers associated with aging, including lipid droplets, amyloid, glycogen deposition, and fibrosis, in the brain, kidneys, liver, ...
One option to consider is refinancing to a conventional 15-year, fixed-rate loan ... One point is equal to 1% of your loan amount. Buying points might be worth it if you plan to stay in your ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback